Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001415889-25-003347
Filing Date
2025-02-07
Accepted
2025-02-07 16:15:38
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 7642
  Complete submission text file 0001415889-25-003347.txt   9443
Mailing Address 6005 HIDDEN VALLEY ROAD SUITE 110 CARLSBAD CA 92011
Business Address 6005 HIDDEN VALLEY ROAD SUITE 110 CARLSBAD CA 92011 858-293-4900
Design Therapeutics, Inc. (Subject) CIK: 0001807120 (see all company filings)

EIN.: 823929248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92462 | Film No.: 25601927
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O DESIGN THERAPEUTICS, INC. 6005 HIDDEN VALLEY ROAD, SUITE 110 CARLSBAD CA 92011
Business Address C/O DESIGN THERAPEUTICS, INC. 6005 HIDDEN VALLEY ROAD, SUITE 110 CARLSBAD CA 92011 858-293-4900
Light Irrevocable Trust #1 dated April 22, 2019 (Filed by) CIK: 0001849306 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A